Kymera Therapeutics, Inc. announced on June 25, 2025, an exclusive option and license agreement with Gilead Sciences, Inc. to develop and commercialize a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) for oncology. This program has broad potential in breast cancer and other solid tumors, aiming to remove CDK2 rather than just inhibiting its function.
Under the terms, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments, plus tiered royalties on net product sales. Kymera will lead all research activities for the CDK2 program, with Gilead gaining global rights upon option exercise. This collaboration validates Kymera's platform in oncology and provides significant non-dilutive funding.
On the same day, Kymera provided an update on its IRAK4 partnership with Sanofi. Sanofi will advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing next year, and will not advance KT-474. KT-485 demonstrated increased selectivity and potency with a favorable safety profile in preclinical testing compared to KT-474.
Kymera achieved a $20 million milestone in the second quarter of 2025 related to preclinical activities associated with KT-485. Kymera is eligible to receive up to $975 million in potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the start of Phase 1 clinical testing, and may opt-in to a 50/50 development and profit share of KT-485 in the U.S.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.